IRIS Accounts Production v25.1.3.33 08543096 director 1.6.23 31.5.24 31.5.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh085430962023-05-31085430962024-05-31085430962023-06-012024-05-31085430962022-05-31085430962022-06-012023-05-31085430962023-05-3108543096ns15:EnglandWales2023-06-012024-05-3108543096ns14:PoundSterling2023-06-012024-05-3108543096ns10:Director12023-06-012024-05-3108543096ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3108543096ns10:SmallEntities2023-06-012024-05-3108543096ns10:AuditExemptWithAccountantsReport2023-06-012024-05-3108543096ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3108543096ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3108543096ns10:FullAccounts2023-06-012024-05-3108543096ns10:RegisteredOffice2023-06-012024-05-3108543096ns5:CurrentFinancialInstruments2024-05-3108543096ns5:CurrentFinancialInstruments2023-05-3108543096ns5:Non-currentFinancialInstruments2024-05-3108543096ns5:Non-currentFinancialInstruments2023-05-3108543096ns5:ShareCapital2024-05-3108543096ns5:ShareCapital2023-05-3108543096ns5:RetainedEarningsAccumulatedLosses2024-05-3108543096ns5:RetainedEarningsAccumulatedLosses2023-05-3108543096ns5:FurnitureFittings2023-06-012024-05-3108543096ns5:ComputerEquipment2023-06-012024-05-3108543096ns5:FurnitureFittings2023-05-3108543096ns5:ComputerEquipment2023-05-3108543096ns5:FurnitureFittings2024-05-3108543096ns5:ComputerEquipment2024-05-3108543096ns5:FurnitureFittings2023-05-3108543096ns5:ComputerEquipment2023-05-3108543096ns5:CostValuation2023-05-3108543096ns5:WithinOneYearns5:CurrentFinancialInstruments2024-05-3108543096ns5:WithinOneYearns5:CurrentFinancialInstruments2023-05-3108543096ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2024-05-3108543096ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-05-3108543096ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-05-3108543096ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-05-31
REGISTERED NUMBER: 08543096 (England and Wales)


















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MAY 2024

FOR

APTUM BIOLOGICS LIMITED

APTUM BIOLOGICS LIMITED (REGISTERED NUMBER: 08543096)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Chartered Accountants' Report 6

APTUM BIOLOGICS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MAY 2024







DIRECTOR: Dr S Litvinov





REGISTERED OFFICE: 1st Floor
Chilworth Point
1 Chilworth Road
Southampton
Hampshire
SO16 7JQ





REGISTERED NUMBER: 08543096 (England and Wales)





ACCOUNTANTS: Rothmans LLP
Chartered Accountants
Chilworth Point
1 Chilworth Road
Southampton
SO16 7JQ

APTUM BIOLOGICS LIMITED (REGISTERED NUMBER: 08543096)

BALANCE SHEET
31 MAY 2024

2024 2023
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 961 1,148
Investments 5 63 63
1,024 1,211

CURRENT ASSETS
Stocks 41,974 52,452
Debtors 6 35,848 15,297
Cash at bank 805 12,999
78,627 80,748
CREDITORS
Amounts falling due within one year 7 56,892 53,738
NET CURRENT ASSETS 21,735 27,010
TOTAL ASSETS LESS CURRENT
LIABILITIES

22,759

28,221

CREDITORS
Amounts falling due after more than one
year

8

14,934

25,626
NET ASSETS 7,825 2,595

CAPITAL AND RESERVES
Called up share capital 11 11
Retained earnings 7,814 2,584
SHAREHOLDERS' FUNDS 7,825 2,595

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 23 May 2025 and were signed by:





Dr S Litvinov - Director


APTUM BIOLOGICS LIMITED (REGISTERED NUMBER: 08543096)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2024

1. STATUTORY INFORMATION

Aptum Biologics Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

REVENUE RECOGNITION
Turnover is the amount derived from providing software for biology testing, and stated after trade discounts and net of VAT.

Revenue is recognised when the amount of revenue can be measured reliably and it is probable that the economic benefits associated with the transaction will flow to the entity.

TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on reducing balance
Computer equipment - 25% on reducing balance

Tangible fixed assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost included expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

The assets' residual values, useful lives and depreciation methods are reviewed and if appropriate are adjusted if there is an indication of a significant change since the last reporting date.

INVESTMENTS IN SUBSIDIARIES
Investments in subsidiary undertakings are recognised at cost.

STOCKS
Stock and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

TAXATION
Taxation for the year comprises current tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

RESEARCH AND DEVELOPMENT
Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is written off in the year in which it is incurred.

FOREIGN CURRENCIES
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

SHORT TERM DEBTORS AND CREDITORS
Debtors and creditors receivable and payable within one year or upon demand are recorded at transaction price whether or not a rate of interest is charged on the balance. Any losses arising from impairment are recognised in the income statement in other operating expenses.

APTUM BIOLOGICS LIMITED (REGISTERED NUMBER: 08543096)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2023 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 June 2023 366 3,592 3,958
Additions 134 - 134
At 31 May 2024 500 3,592 4,092
DEPRECIATION
At 1 June 2023 160 2,650 2,810
Charge for year 85 236 321
At 31 May 2024 245 2,886 3,131
NET BOOK VALUE
At 31 May 2024 255 706 961
At 31 May 2023 206 942 1,148

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 June 2023
and 31 May 2024 63
NET BOOK VALUE
At 31 May 2024 63
At 31 May 2023 63

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 9,414 6,732
Other debtors 6,741 2,630
Director's current account 18,714 5,935
VAT 979 -
35,848 15,297

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts 11,657 10,562
Trade creditors 2,344 11,174
Tax - 560
VAT - 429
Other creditors 16,024 15,022
Intercompany creditors 23,744 14,441
Accrued expenses 3,123 1,550
56,892 53,738

APTUM BIOLOGICS LIMITED (REGISTERED NUMBER: 08543096)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2024

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2023
£    £   
Bank loans - 1-2 years 12,345 11,243
Bank loans - 2-5 years 2,589 14,383
14,934 25,626

9. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

At the beginning of the year the Director owed the company £5,935. During the year the Director introduced capital of £66,716 and after withdrawing the sum of £79,320 including interest of £175, an amount of £18,714 was owed to the company at the balance sheet date.

CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR
ON THE UNAUDITED FINANCIAL STATEMENTS OF
APTUM BIOLOGICS LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Aptum Biologics Limited for the year ended 31 May 2024 which comprise the Statement of Income and Retained Earnings, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Aptum Biologics Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Aptum Biologics Limited and state those matters that we have agreed to state to the director of Aptum Biologics Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Aptum Biologics Limited and its director for our work or for this report.

It is your duty to ensure that Aptum Biologics Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Aptum Biologics Limited. You consider that Aptum Biologics Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Aptum Biologics Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Rothmans LLP
Chartered Accountants
Chilworth Point
1 Chilworth Road
Southampton
SO16 7JQ


Date: .............................................